# Baxter International Inc. (BAX)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $10.42B  
**Price:** $20.31 (+1.40%)

> Baxter International Inc. is a healthcare company that provides essential medical products and therapies used in hospitals, clinics, and home care settings. Baxter International Inc. offers acute and chronic dialysis treatments, sterile intravenous solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, and surgical products such as hemostats and sealants. The company also supplies smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. Its portfolio supports critical care, perioperative care, renal care, and medication delivery across a broad range of healthcare environments. Baxter International Inc. serves healthcare providers and patients with products designed to support treatment, monitoring, and recovery in routine and specialized medical settings. Headquartered in Deerfield, Illinois, Baxter International Inc. plays a significant role in the global medical products market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $11.24B | $3.38B | -$308M | -$957M | — |
| 2024 | $10.64B | $3.98B | $14M | -$649M | — |
| 2023 | $10.36B | $4.15B | $707M | $2.66B | — |
| 2022 | $10.06B | $3.55B | -$2.85B | -$2.43B | — |
| 2021 | $12.15B | $4.72B | $1.35B | $1.28B | — |
| 2020 | $11.67B | $4.59B | $1.62B | $1.10B | — |
| 2019 | $11.36B | $4.76B | $1.77B | $1.00B | — |
| 2018 | $11.10B | $4.76B | $1.58B | $1.55B | — |
| 2017 | $10.58B | $4.47B | $1.29B | $602M | — |
| 2016 | $10.16B | $4.12B | $745M | $4.96B | — |
| 2015 | $9.97B | $4.15B | $449M | $968M | — |
| 2014 | $16.67B | $4.58B | $656M | $2.50B | — |
| 2013 | $15.26B | $4.16B | $496M | $2.01B | — |
| 2012 | $14.19B | $7.13B | — | $2.33B | — |
| 2011 | $13.89B | $7.05B | — | $2.22B | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $20.05B | $13.95B | $6.13B | $1.97B | $9.44B |
| 2024 | $25.78B | $18.76B | $6.96B | $1.76B | $13.18B |
| 2023 | $28.28B | $19.81B | $8.40B | $3.08B | $13.86B |
| 2022 | $28.29B | $22.39B | $5.83B | $1.62B | $16.70B |
| 2021 | $33.52B | $24.40B | $9.08B | $2.95B | $17.75B |
| 2020 | $20.02B | $11.29B | $8.69B | $3.73B | $6.23B |
| 2019 | $18.19B | $10.28B | $7.88B | $3.33B | — |
| 2018 | $15.72B | $7.85B | $7.84B | $1.84B | — |
| 2017 | $17.11B | $8.00B | $9.12B | $3.39B | — |
| 2016 | $15.55B | $7.26B | $8.29B | $2.80B | — |
| 2015 | $20.96B | $12.12B | $8.85B | $2.21B | — |
| 2014 | $26.14B | $18.02B | $8.12B | $2.92B | — |
| 2013 | $25.22B | $16.76B | $8.46B | $2.73B | — |
| 2012 | $20.39B | $13.45B | $6.94B | $3.27B | — |
| 2011 | $19.07B | $12.49B | $6.58B | $2.90B | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $845M | — | — |
| 2024 | $1.02B | — | — |
| 2023 | $1.73B | — | — |
| 2022 | $1.21B | — | — |
| 2021 | $2.22B | — | — |
| 2020 | $1.87B | — | — |
| 2019 | $2.10B | — | — |
| 2018 | $2.02B | — | — |
| 2017 | $1.71B | — | — |
| 2016 | $1.65B | — | — |
| 2015 | $1.77B | — | — |
| 2014 | $3.21B | — | — |
| 2013 | $3.20B | — | — |
| 2012 | $3.11B | — | — |
| 2011 | $2.82B | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/BAX)